WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Technology Internet Technology Tuesday, October 23, 2018 
Add Press Release News | News Feeds Feeds | Email This News Email


Frost & Sullivan Publishes Immediate Update Report on Kadimastem Ltd.: World's First successful transplant of embryonic stem cells in ALS patients
Thursday, October 11, 2018

Due to a higher probability of success in current clinical trials (results due in mid-2019), target price increased to NIS 1.12

Equity Research is published in the framework of the Tel Aviv Stock Exchange (TASE) Analysis Program

TEL AVIV, Israel, Oct. 11, 2018 /PRNewswire/ -- The TASE analysis project was launched in 2016 in order to raise the investors' level of knowledge of TASE listed technology and life-science companies and the markets in which the companies operate, thus creating appropriate pricing and increasing the exposure of investors from Israel and abroad. Its goal is to encourage investments in these companies by removing the barrier of lacking understanding in the market.

In order to maintain professional, independent and unbiased analysis, the companies signed an agreement with the TASE to receive the analysis services for an obligatory period of two years. The companies cannot withdraw from the project during this period. The analysis is funded by the companies surveyed with funding from the Chief Scientist and the TASE.

Summary of Highlights

Kadimastem published an immediate report on October 9, 2018. The company reported on the world's first transplantation of embryonic stem cells and the completion of 5 patients' enrollment for Cohort A. The very success of the implantation is an initial confirmation of the safety of cellular therapy:

    --  The company performed the world's first astrocytes cell transplantation
        in the first ALS patient. Final results will be published in mid-2019
        for the first group
    --  Cell transplantation is a scientific breakthrough in that it is first
        performed in humans as part of a clinical trial. The innovative
        technology developed in KadimaStam by Prof. Michel Revel, Chief
        Scientist of the company, and Dr. Michal Yizrael, Deputy Director
        General of R & D of Neurodegenerative Diseases, is a unique approach to
        cell transplantation that produces healthy cells that function instead
        of cells that have been infected with the disease, ALS, thus forming a
        kind of spare part in the nervous system.
    --  The clinical trial examines the safety and efficacy of cellular therapy
        after cell transplantation. The company has invested more than $ 40
        million to develop the company's technology.
    --  In the first analysis report we published on June 12, 2018, we reviewed
        all activities of Kadimastem with details regarding the trial and its
        significance.

In our view, this means confirming our assessment of the progress of the clinical trial. The expected results of the experiment in mid-2019 are known and included in our economic model. However, the recruitment of 5 patients and successful transplantation increases the probability of success of the entire clinical trial. We will examine the continued recruitment of patients and analyze it in our upcoming quarterly report.

Thus, we raise our valuation for the company to NIS 69 million (our previous estimate was NIS 52 million), at a target price of NIS 1.03 to NIS 1.21; Average of NIS 1.12.

    --  See more for details in our Initiation of Coverage report dated June 12,
        2018 for details on our valuation methodology.

About the company - Kadimastem Ltd. (hereinafter "Kadimastem" or "the company") is a clinical stage biopharmaceutical company that specializes in developing different types of human body cells (known as differentiated cells) - such as neural cells (e.g. oligodendrocytes and astrocytes) and insulin secreting beta cells, derived from human embryonic stem cells. The company has its technological platform and two current stem cell based therapies in research phase - AstroRx (consists of astrocytes, a type of brain cell) and Encapsulin (insulin secreting beta cells) for treating amyotrophic lateral sclerosis (ALS) and diabetes respectively.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion

Contact:
Kristi Cekani
Corporate Communications - Frost & Sullivan, Europe
P: +39.02.4851.6133
E: kristi.cekani@frost.com
http://www.frost.com

View original content:http://www.prnewswire.com/news-releases/frost--sullivan-publishes-immediate-update-report-on-kadimastem-ltd-worlds-first-successful-transplant-of-embryonic-stem-cells-in-als-patients-300729539.html

SOURCE Frost & Sullivan



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav Stratosphere Networks CISO Raises Funds for 2019 Mission Trip to Ecuador | Oct 23, 2018
Nav Standard Missile-2 defeats aerial targets in South Korean Navy exercises | Oct 23, 2018
Nav Raytheon's Rolling Airframe Missile to defend Armada de México patrol frigate | Oct 23, 2018
Nav Delta Care Rx Announces Launch of Virtual Assistant App for Hospice Clinicians | Oct 23, 2018
Nav Allot to Narrow the Technological Divide in Rural Territories With Improved Web Security and Network Performance | Oct 23, 2018
Nav Experian helps organizations maximize the potential of their data through the power of machine learning | Oct 23, 2018
Nav Oracle Cements Commitment to Next Generation of Enterprise Cloud | Oct 23, 2018
Nav ROAMING MAN Announces New G3 Wifi HotSpot On Sale | Oct 23, 2018
Nav Geoswift Enables Customers to Scale Business Growth with Geoswift X, its new suite of Cross-Border Payment Solutions | Oct 23, 2018
Nav Global Companies Drive Faster Innovation with Oracle Cloud | Oct 23, 2018
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News